Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pulse Biosciences has completed patient enrollment in the PRECISE-BTN clinical study, which evaluates the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The first patient has successfully completed their final 12-month follow-up visit, marking a significant milestone for the study.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful completion of patient enrollment in the clinical study.
  • First patient completed the final 12-month follow-up visit.
  • Novel technology could improve treatment for benign thyroid nodules.

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Saraso

Frequently Asked Questions

What is the PRECISE-BTN clinical study?

The PRECISE-BTN clinical study evaluates the nPulse™ Vybrance™ system for treating symptomatic benign thyroid nodules.

What technology does Pulse Biosciences use?

Pulse Biosciences uses proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology.

What milestone was recently achieved in the study?

The first patient enrolled completed their final 12-month follow-up visit.

What condition is being targeted in this study?

The study targets symptomatic benign thyroid nodules.

ShareAdd on Google
Tags: PLSE Viatris Investor Conferences Healthcare Pulse Biosciences nPulse thyroid nodules clinical study benign thyroid nodules
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$102M liquidity · $6M/mo burn
~15 mo
Low dilution risk